LGVN News and Press, Longeveron Inc. From 04/08/24

MIAMI, April 08, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that the Company’s CEO, Wa’el Hashad, issued the following letter to Longeveron shareholders. Dear Shareholde...

Longeveron recently released its full-year results for the period ended December 31, 2023, and provided a corporate update The update outlined the company’s plans to prioritize the development of Lomecel-B(TM) in Hypoplastic Left Heart Syndrome (“HLHS”), a rare, pediatric c...

Scientists at Texas A&M University have found evidence suggesting that there may be a link between Alzheimer’s disease risk and type 2 diabetes. This is backed by data from a separate study , which found that roughly 81% of individuals living with Alzheimer’s disease also hav...

2024-03-26 09:02:03 ET Longeveron LLC (LGVN) announced stock split at a ratio of 1-for-10 on 2024-03-27 ... Full story available on KlickAnalytics.com

Longeveron (NASDAQ: LGVN) , a clinical-stage biotechnology company developing regenerative medicines for unmet medical needs, has announced a 1-for-10 reverse split of the company’s Class A common stock. The move was approved by the company’s board of directors during a special stoc...

2024-03-19 17:21:06 ET More on Longeveron Longeveron Inc. (LGVN) Q4 2023 Earnings Call Transcript Longeveron stock plummets on $2.36M registered direct offering priced at $1.62/share Read the full article on Seeking Alpha For further details see: Longever...

2024-03-19 16:07:50 ET More on Longeveron Longeveron Inc. (LGVN) Q4 2023 Earnings Call Transcript Longeveron stock plummets on $2.36M registered direct offering priced at $1.62/share Read the full article on Seeking Alpha For further details see: Longever...

MIAMI, March 19, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, announced today that the Company’s Board of Directors has appr...

Preliminary research has found that herbicides and pesticides used in farming may be associated with Parkinson’s disease. For their research, the investigators reviewed records from more than 20 million individuals obtained from Medicare. The objective of the researchers was to calcul...

Longeveron (NASDAQ: LGVN) , a clinical-stage biotechnology company developing regenerative medicines for unmet medical needs, has released a financial report for the year ended Dec. 31, 2023; the report also included a corporate update. The report noted that revenues for 2023 totaled $0.7 million...